chromosome 8Q12.1-q21.2 deletion syndrome

disease
On this page

Also known as Branchio-Oto-renal Duane hydrocephalus contiguous gene syndrome

Summary

chromosome 8Q12.1-q21.2 deletion syndrome (MONDO:0010852) is a disease. A subtype of partial deletion of the long arm of chromosome 8 — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namechromosome 8Q12.1-q21.2 deletion syndrome
Mondo IDMONDO:0010852
MeSHC536574
OMIM600257
UMLSC1838346
MedGen333071
GARD0010002
Is cancer (heuristic)no

Also known as: Branchio-Oto-renal Duane hydrocephalus contiguous gene syndrome · chromosome 8Q12.1-q21.2 deletion syndrome

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › chromosomal disordersyndrome caused by partial chromosomal deletion › partial deletion of chromosome 8 › partial deletion of the long arm of chromosome 8 › chromosome 8Q12.1-q21.2 deletion syndrome

Related subtypes (5): trichorhinophalangeal syndrome type II, mesomelia-synostoses syndrome, 8q22.1 microdeletion syndrome, chromosome 8q21.11 deletion syndrome, 8q24.3 microdeletion syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.